Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer

Zin W. Myint; Jill M. Kolesar; Joseph Robert McCorkle; Jianrong Wu; Carleton S. Ellis; Danielle E. Otto; Peng Wang

doi:10.12659/MSM.938091

14 October 2022 : Clinical Research

Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer

Zin W. Myint^12ABCDEFG*, Jill M. Kolesar^23CDE, Joseph Robert McCorkle^2CDE, Jianrong Wu^4C, Carleton S. Ellis^32CDE, Danielle E. Otto^23CDE, Peng Wang^12ACDE

DOI: 10.12659/MSM.938091

Med Sci Monit 2022; 28:e938091

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 7 Association between HSD3B1 genotype risk allele and 1-month, 3-month, and 7-month abiraterone trough levels.

HSD3B1 genotype	N	Mean (tABI)a	P value

	1 Month
0^b	4	7.83	0.398
1^c	6	11.07

	3 Months
0^b	4	12.71	0.678
1^c	5	10.64

	7 Months
0^b	2	9.13	0.386
1^c	4	16.12
^a tABI, trough abiraterone; ^b homozygous (A/A) genotype; ^c heterozygous (C/A) genotype; HSD3B1, hydroxyl-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1.

Back to the Article

Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer

Your Privacy